3 Diagnostics Chain, Integrated Power Utility and Branded Generic Medicines Company Stocks With a Strong Future Roadmap: Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories

Diagnostics, power utility and generics stocks let investors follow companies that serve a growing part of the Indian economy. Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories cover a diagnostics chain, an integrated power utility and a branded generic medicines company.

This list covers three diagnostics, power utility and generics stocks with complete current figures: Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Diagnostics, Power Utility and Generics Stocks?

Diagnostics, power utility and generics stocks are listed companies that run diagnostic centres with pathology and radiology services, generate and distribute electricity in Gujarat and beyond, and sell branded generic medicines in Latin America and other markets. Their earnings depend on test volumes, power demand and prescriptions.

Diagnostics, Power Utility and Generics Stocks at a Glance

On valuation, Caplin Point Laboratories trades at a P/E below the industry P/E, while Vijaya Diagnostic Centre and Torrent Power trade above it, which reflects the growth the market already expects. Readers comparing diagnostics, power utility and generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in diagnostics, power utility and generics stocks can use the coming numbers to test whether growth is holding.

Why Do Diagnostics, Power Utility and Generics Stocks Have a Strong Roadmap in India?

Diagnostics, power utility and generics stocks have a strong roadmap in India because growing health testing, rising power consumption and steady demand for branded generics keep widening the market for these companies.

• Diagnostics. More people take regular tests.
• Power utility. Cities and factories use more electricity.
• Branded generics. Emerging markets buy trusted medicines.

Why Vijaya Diagnostic Centre Features Among These Diagnostics, Power Utility and Generics Stocks

Among the diagnostics, power utility and generics stocks on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.

The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.

Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore.

Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.

Why Torrent Power Features Among These Diagnostics, Power Utility and Generics Stocks

Among the health, electricity and pharma shares on this list, Torrent Power is an integrated power company in Gujarat that generates, transmits and distributes electricity, with operations in Ahmedabad, Surat and Bhiwandi, and a growing renewable energy portfolio.

Revenue rose from Rs 14,493 crore in FY22 to Rs 29,289 crore in FY26, a compound annual growth rate of 19.2%. Net profit grew from Rs 459 crore in FY22 to Rs 2,469 crore in FY26, which works out to a compound annual growth rate of 52.3%.

In the June 2026 quarter, revenue grew 2.4% year on year to Rs 8,205 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 60,947 crore. The stock trades at a P/E of 25.5, above the industry P/E of 21.8.

Roadmap: The company operates a stable distribution franchise and is adding large renewable capacity alongside new thermal and pumped storage projects. Its distribution licences in major cities provide steady cash flows that support these investments.

What to watch: Monitor renewable capacity commissioning and the progress of new generation projects.

Why Caplin Point Laboratories Features Among These Diagnostics, Power Utility and Generics Stocks

Among the three companies on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.

In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%.

Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.

Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What to watch: Follow new US product approvals and currency trends in Latin American markets.

Vijaya Diagnostic Centre vs Torrent Power vs Caplin Point Laboratories on Key Financials

The table below sets the three diagnostics, power utility and generics stocks side by side on revenue, profit and margin, using reported figures.

Vijaya Diagnostic Centre posts the highest return on equity in this group at 18.1%. Torrent Power combines the largest FY26 revenue at Rs 29,289 crore with the fastest revenue growth, a 19.2% compound annual rate. A useful habit with diagnostics, power utility and generics stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pathology, Gujarat power and branded generic stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Diagnostics, Power Utility and Generics Stocks

Every theme carries risks that deserve a check before any decision. For these diagnostics, power utility and generics stocks, the main points are: Long-term health, electricity and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Test volumes. Footfall and test mix can vary with seasons.
• Component costs. Copper, chips and other inputs can move margins.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter diagnostics, power utility and generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Diagnostics, Power Utility and Generics Stocks

Diagnostics, power utility and generics stocks reward investors who follow demand trends, order books and margins together. Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories each have a clear plan to grow. Based on the 4 November 2026 close, Vijaya Diagnostic Centre trades at Rs 1,424.6, Torrent Power at Rs 1,234.4 and Caplin Point Laboratories at Rs 2,416.1. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these diagnostics, power utility and generics stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track diagnostics, power utility and generics stocks, set price alerts and get research-backed stock ideas.

What are diagnostics, power utility and generics stocks?

Ans. Diagnostics, power utility and generics stocks are listed companies that run diagnostic centres with pathology and radiology services, generate and distribute electricity in Gujarat and beyond, and sell branded generic medicines in Latin America and other markets. Their earnings depend on test volumes, power demand and prescriptions. This list looks at three of them, Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.

Which diagnostics, power utility and generics stocks are covered in this list?

Ans. This list covers Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Based on the 4 November 2026 close, Vijaya Diagnostic Centre traded at Rs 1,424.6, Torrent Power at Rs 1,234.4 and Caplin Point Laboratories at Rs 2,416.1. Their return on equity ranges from 12.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 19.2%.

Why do diagnostics, power utility and generics stocks have a strong future roadmap in India?

Ans. Diagnostics, power utility and generics stocks have a strong roadmap in India because growing health testing, rising power consumption and steady demand for branded generics keep widening the market for these companies. The main drivers are as follows. Diagnostics. More people take regular tests. Power utility. Cities and factories use more electricity. Branded generics. Emerging markets buy trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Vijaya Diagnostic Centre performed financially?

Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

How has Torrent Power performed financially?

Ans. Revenue rose from Rs 14,493 crore in FY22 to Rs 29,289 crore in FY26, a compound annual growth rate of 19.2%. Net profit grew from Rs 459 crore in FY22 to Rs 2,469 crore in FY26, which works out to a compound annual growth rate of 52.3%. In the June 2026 quarter, revenue grew 2.4% year on year to Rs 8,205 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 60,947 crore. The stock trades at a P/E of 25.5, above the industry P/E of 21.8. Looking ahead, the company operates a stable distribution franchise and is adding large renewable capacity alongside new thermal and pumped storage projects. Its distribution licences in major cities provide steady cash flows that support these investments.

How has Caplin Point Laboratories performed financially?

Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What risks should investors check before buying diagnostics, power utility and generics stocks?

Ans. Investors should check a few risks before buying diagnostics, power utility and generics stocks. Test volumes. Footfall and test mix can vary with seasons. Component costs. Copper, chips and other inputs can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of diagnostics, power utility and generics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.